This trial investigated the activity and toxicity of gemcitabine in previously untreated elderly (> 70 years) patients with advanced (stage IIIB-IV) non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: From January 1997 to July 1998, 46 patients with advanced NSCLC aged over 70 years with a performance status of 0-2 were entered into the study. Gemcitabine 1000 mg/m2 was administered as a 30-min infusion once a week for 3 weeks followed by a week of rest; cycles were repeated every 4 weeks. RESULTS: Forty-four patients were evaluable for response. One complete response and nine partial responses were observed, for an overall response rate of 22.2% (95% C.I.: 11.3-37.5). The median time to disease progression was 5.1 months (95% C.I.: 3.5-6.7), the median duration of response was 6.3 months, and the median overall survival time 6.75 months (95% C.I.: 5.3-8.2). All patients were evaluable for toxicity (184 cycles, median = 3 cycles/patient) and no grade 4 hematologic toxicities were reported. WHO grade 3 leukopenia, neutropenia and anemia occurred in 3.3, 0.5 and 1.1% of cycles, respectively. Grade 3 skin rash occurred in 4.3% of patients. These side effects led to treatment discontinuation in two patients. CONCLUSION: Our data show that gemcitabine is active and well tolerated in patients aged over 70 years with advanced NSCLC.

Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. A Multicenter phase II study / S., Ricci; A., Antonuzzo; L., Galli; C., Tibaldi; M., Bertuccelli; A., Lopes Pegna; S., Petruzzelli; R., Algeri; V., Bonifazi; M. L., Fioretto; C., Orlandini; Conte, Pierfranco. - In: LUNG CANCER. - ISSN 0169-5002. - STAMPA. - 27:(2000), pp. 75-80.

Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. A Multicenter phase II study.

CONTE, Pierfranco
2000-01-01

Abstract

This trial investigated the activity and toxicity of gemcitabine in previously untreated elderly (> 70 years) patients with advanced (stage IIIB-IV) non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: From January 1997 to July 1998, 46 patients with advanced NSCLC aged over 70 years with a performance status of 0-2 were entered into the study. Gemcitabine 1000 mg/m2 was administered as a 30-min infusion once a week for 3 weeks followed by a week of rest; cycles were repeated every 4 weeks. RESULTS: Forty-four patients were evaluable for response. One complete response and nine partial responses were observed, for an overall response rate of 22.2% (95% C.I.: 11.3-37.5). The median time to disease progression was 5.1 months (95% C.I.: 3.5-6.7), the median duration of response was 6.3 months, and the median overall survival time 6.75 months (95% C.I.: 5.3-8.2). All patients were evaluable for toxicity (184 cycles, median = 3 cycles/patient) and no grade 4 hematologic toxicities were reported. WHO grade 3 leukopenia, neutropenia and anemia occurred in 3.3, 0.5 and 1.1% of cycles, respectively. Grade 3 skin rash occurred in 4.3% of patients. These side effects led to treatment discontinuation in two patients. CONCLUSION: Our data show that gemcitabine is active and well tolerated in patients aged over 70 years with advanced NSCLC.
27
75
80
Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. A Multicenter phase II study / S., Ricci; A., Antonuzzo; L., Galli; C., Tibaldi; M., Bertuccelli; A., Lopes Pegna; S., Petruzzelli; R., Algeri; V., Bonifazi; M. L., Fioretto; C., Orlandini; Conte, Pierfranco. - In: LUNG CANCER. - ISSN 0169-5002. - STAMPA. - 27:(2000), pp. 75-80.
S., Ricci; A., Antonuzzo; L., Galli; C., Tibaldi; M., Bertuccelli; A., Lopes Pegna; S., Petruzzelli; R., Algeri; V., Bonifazi; M. L., Fioretto; C., Orlandini; Conte, Pierfranco
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/615549
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 91
  • ???jsp.display-item.citation.isi??? 80
social impact